TY - JOUR
T1 - Bupropion-induced erythema multiforme
AU - Lineberry, Maj Timothy W.
AU - Peters, Gerald E.
AU - Bostwick, John Michael
PY - 2001/1/1
Y1 - 2001/1/1
N2 - The high rate of dermatologic adverse effects associated with bupropion use may extend to its sustained-release preparation, currently prescribed extensively for smoking cessation as well as for treatment of depressive conditions. We report what we believe to be the first case, in a 31-year-old woman, of erythema multiforme after administration of sustained-release bupropion (Wellbutrin SR) for treatment of depression. This report emphasizes that prescribers must aggressively follow up their patients who have rashes or urticaria, discontinuing the medication as soon as erythema multiforme is suspected and watching closely for the emergence of potentially life-threatening dermatologic conditions.
AB - The high rate of dermatologic adverse effects associated with bupropion use may extend to its sustained-release preparation, currently prescribed extensively for smoking cessation as well as for treatment of depressive conditions. We report what we believe to be the first case, in a 31-year-old woman, of erythema multiforme after administration of sustained-release bupropion (Wellbutrin SR) for treatment of depression. This report emphasizes that prescribers must aggressively follow up their patients who have rashes or urticaria, discontinuing the medication as soon as erythema multiforme is suspected and watching closely for the emergence of potentially life-threatening dermatologic conditions.
UR - http://www.scopus.com/inward/record.url?scp=0034995233&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034995233&partnerID=8YFLogxK
U2 - 10.4065/76.6.664
DO - 10.4065/76.6.664
M3 - Article
C2 - 11393509
AN - SCOPUS:0034995233
SN - 0025-6196
VL - 76
SP - 664
EP - 666
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 6
ER -